Skip to content

Haemonetics HAE Dispositions of property, plant, and equipment

Dispositions of property, plant, and equipment at other companies

Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Repligen logo
RepligenRGEN
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$346.4M+4.8%
Gross profit$198.2M+2.7%
Operating income$67.4M+14.2%
Net income$44.7M+19.3%
EPS (diluted)$0.95+28.4%

Balance sheet

See full
Cash & equivalents$245.4M-20.0%
Total debt$1.3B-0.7%
Total equity$796.3M-3.0%
Total assets$2.4B-2.2%

Cash flow

See full
Operating cash flow$70.9M-39.1%
CapEx$17.7M+12.9%
Free cash flow$53.3M-47.2%

Valuation

See full
Market cap$3.31B-18.0%

Profitability

See full
Gross margin59%+4.0pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin19.5%+9.1pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.6×0.0×
Current ratio+1.3×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment.

The official record: Haemonetics’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Haemonetics's dispositions of property, plant, and equipment.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Haemonetics's dispositions of property, plant, and equipment?
Haemonetics (HAE) reported dispositions of property, plant, and equipment of $526K in Q1 2026.
How has Haemonetics's dispositions of property, plant, and equipment changed year-over-year?
Haemonetics's dispositions of property, plant, and equipment decreased by 78.5% year-over-year, from $2.45M to $526K.
What is the long-term trend for Haemonetics's dispositions of property, plant, and equipment?
Over 3 years (2022 to 2026), Haemonetics's dispositions of property, plant, and equipment has grown at a -12.1% compound annual growth rate (CAGR), from $2.02M to $1.38M.